Welcome to our dedicated page for Neurocrine Biosciences SEC filings (Ticker: NBIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Neurocrine Biosciences’ SEC disclosures can feel like a clinical trial in itself—hundreds of pages of neurology jargon, R&D cost tables, and patent-expiry timelines bury crucial signals such as INGREZZA revenue momentum and cash runway for its congenital adrenal hyperplasia program. If you have ever asked, “Where can I find Neurocrine Biosciences’ quarterly earnings report 10-Q filing?” or “How do I track NBIX insider trading Form 4 transactions in real time?”, you know the challenge.
Stock Titan’s AI does the heavy lifting. Our engine reads every new 10-K, 10-Q, 8-K, proxy and S-8 the moment it lands on EDGAR, then translates complex language into clear takeaways. Instead of combing through footnotes, you receive concise explanations, cash-flow highlights, and instant alerts on Neurocrine Biosciences Form 4 insider transactions real-time. Key documents and what you’ll learn are grouped for fast access:
- Annual report 10-K simplified – spot INGREZZA sales trends, R&D tax credits and patent life in minutes.
- Quarterly earnings report 10-Q filing – compare sequential revenue, trial spend and liquidity ratios without crunching spreadsheets.
- 8-K material events explained – understand clinical-trial readouts or FDA updates as soon as they post.
- Executive stock transactions Form 4 – monitor buying or selling that may signal management’s conviction.
- Proxy statement executive compensation – review incentive structures tied to pipeline milestones.
Whether you need understanding Neurocrine Biosciences SEC documents with AI before the market opens or a deeper dive into NBIX earnings report filing analysis for strategy meetings, Stock Titan delivers complete, continuously updated coverage—no biotech PhD required.
Robinhood Markets, Inc. (HOOD) has filed a Form 144 indicating the intended sale of 250,000 common shares with an estimated aggregate market value of $23.6 million. The shares are slated to be sold through Morgan Stanley Smith Barney LLC on or about 07 July 2025 on the NASDAQ.
The filing lists 767,047,021 shares outstanding; the contemplated transaction therefore represents roughly 0.03 % of the float, suggesting limited dilution or trading-volume impact. The notice also discloses that 750,000 shares were sold on 01 July 2025 for $69.95 million under a Rule 10b5-1 plan attributed to Vladimir Tenev.
- The current sale plus the earlier disposal totals 1.0 million shares, generating about $93.5 million for the insider within a single week.
- The seller affirms awareness of no undisclosed adverse information, and reliance on a written 10b5-1 plan mitigates insider-trading risk.
While purely administrative and not a guarantee of execution, the filing signals continued insider selling activity. Investors often watch such patterns for sentiment clues, even when the share count is immaterial relative to the company’s overall capitalization.
GitLab Inc. (NASDAQ: GTLB) has filed a Form 144 disclosing the proposed sale of 1,214 shares of its Class A common stock under Rule 144. The shares, valued at roughly $55,249, account for less than 0.001 % of the company’s approximately 146.1 million shares outstanding, making the transaction immaterial to GitLab’s overall float and market liquidity.
The seller acquired the stock as restricted stock units (RSUs) on 27 June 2025 and intends to execute the sale through Morgan Stanley Smith Barney LLC on or after 2 July 2025. No additional sales by this filer have occurred in the past three months. The notice states that the filer is unaware of any non-public adverse information, suggesting this is a routine liquidity event rather than a signal of strategic change.
FAQ
What is the current stock price of Neurocrine Biosciences (NBIX)?
What is the market cap of Neurocrine Biosciences (NBIX)?
What is the core focus of Neurocrine Biosciences Inc?
Which therapeutic areas does Neurocrine primarily target?
How does Neurocrine differentiate itself in the biopharmaceutical industry?
What role does clinical research play in Neurocrine's strategy?
Does Neurocrine have a diversified product portfolio?
How are Neurocrine's therapies developed?
Who are the typical beneficiaries of Neurocrine's treatments?
How does Neurocrine ensure the quality and reliability of its products?
